Pirating on Rough Waters: CAR Therapy for Myeloid Neoplasms

Pirating on Rough Waters: CAR Therapy for Myeloid Neoplasms is organized by Cleveland Clinic Center for Continuing Education.

Release Date: January 17, 2019
Expiration Date: January 17, 2021

Estimated Time of Completion: 30 minutes

Accreditation:
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description:
Pirating on Rough Waters: CAR Therapy for Myeloid Neoplasms webcast, part of the Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies online series, will review CAR design and CD19 CAR experience, as well as AML CAR target identification challenges.

Learning Objective:
• Review basic CAR design and CD19 CAR experience
• Describe AML CAR target identification challenges
• Identify BiTE and DART therapeutic approaches in AML
• Highlight AML CAR clinical experience to date and future AML CAR (ASH 2018 and beyond)
• Critically appraise results of research on the evolving role of chimeric antigen receptor-T cell (CAR-T) therapy in myeloid malignancies